Monoclonal antibody therapy in rheumatoid arthritis

British Journal of Rheumatology

Volumn 37, Issue 5, 1998, Pages 484-490

  Choy, E H S ^a,b   Kingsley, G H ^a   Panayi, G S ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

Author keywords

Monoclonal antibodies; Rheumatoid arthritis; Treatment

Indexed keywords

LYMPHOCYTE ANTIBODY; MONOCLONAL ANTIBODY; OKT 4; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ARTICLE; INFLAMMATION; LYMPHOCYTOPENIA; MEDIATOR; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYNOVITIS;

EID: 0031874950     PISSN: 02637103     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/37.5.484     Document Type: Article

References (47)

1. McIntosh E. The cost of rheumatoid arthritis. Br J Rheumatol 1996;35:781-90.
2. Scott DL, Symmons DP, Coulton BL, Popert AJ. Long-term outcome of treating rheumatoid arthritis: results after 20 years. Lancet 1987;i:1108-11.
3. Pincus T, Marcum SB, Callahan LF. Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone. J Rheumatol 1992;19:1885-94.
4. Isler P, Vey E, Zhang J, Dayer J. Cell surface glyco-proteins expressed on activated human T cells induce production of interleukin-1 beta by monocytic cells: a possible role of CD69. Eur Cytokine Netw 1993;4:15-23.
5. Paulnock DM. Macrophage activation by T cells. Curr Opin Immunol 1992;4:344-9.
6. Brennan FM, Feldmann M. Cytokines in autoimmunity. Curr Opin Immunol 1992;4:754-9.
7. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256:495-7.
8. Kavanaugh AF, Davis LS, Nichols LA et al. Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1. Arthritis Rheum 1994;37:992-9.
9. Kavanaugh AF, Schulze-Koops H, Davis LS, Lipsky PE. Repeat treatment of rheumatoid arthritis patients with a murine anti-intercellular adhesion molecule-1 monoclonal antibody. Arthritis Rheum 1997;40:849-53.
10. Winter G, Milstein C. Man-made antibodies. Nature 1991;349:293-9.
11. Marks C, Marks JD. Phage libraries - a new route to clinically useful antibodies. N Engl J Med 1996;335: 730-3.
12. Brennan FM, Maini RN, Feldmann M. TNF alpha - a pivotal role in rheumatoid arthritis? Br J Rheumatol 1992;31:293-8.
13. Keffer J, Probert L, Cazlaris H et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 1991;10:4025-31.
14. Chu CQ, Field M, Allard S, Abney E, Feldmann M, Maini RN. Detection of cytokines at the cartilage/pannus junction in patients with rheumatoid arthritis: implications for the role of cytokines in cartilage destruction and repair. Br J Rheumatol 1992;31:653-61.
15. Elliott MJ, Maini RN, Feldmann M et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
16. Rankin EC, Choy EH, Kassimos D et al. The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol 1995;34:334-42.
17. Choy EHS, Kassimos D, Kingsley GH et al. The effect of an engineered human anti-tumour necrosis factor alpha (TNFα) antibody (Ab) on interleukin-6 (IL-6) and bone markers in rheumatoid arthritis (RA) patients. Arthritis Rheum 1995;38(suppl.):S185.
18. Lorenz HM, Antoni C, Valerius T et al. In vivo blockade of TNF-alpha by intravenous infusion of a chimeric monoclonal TNF-alpha antibody in patients with rheumatoid arthritis. Short term cellular and molecular effects. J Immunol 1996;156:1646-53.
19. Elliott MJ, Maini RN, Feldmann M et al. Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis. Lancet 1994;344:1125-7.
20. Rankin ECC, Choy EHS, Sopwith M, Vetterlein O, Panayi GS, Isenberg DA. Repeated doses of 10mg/kg of an engineered human anti-TNFα antibody, CDP571, in RA patients are safe and effective. Arthritis Rheum 1995;38(suppl.):S185.
21. Rankin ECC, Ravirajan CT, Ehrenstein MR et al. Serological effects following treatment with an engineered human anti-TNFα antibody, CDP571 in patients with rheumatoid arthritis (RA). Br J Rheumatol 1995; 34(suppl. 1):101.
22. Maini RN, Breedveld FC, Kalden JR et al. Low dose methotrexate (MTX) suppresses anti-globulin responses and potentiates efficacy of a chimeric monoclonal anti-TNFα antibody (cA2) given repeatedly in rheumatoid arthritis (RA). Arthritis Rheum 1997;40(suppl.):S126.
23. Dasgupta B, Corkill M, Kirkham B, Gibson T, Panayi G. Serial estimation of interleukin 6 as a measure of systemic disease in rheumatoid arthritis. J Rheumatol 1992; 19:22-5.
24. Wendling D, Racadot E, Wijdenes J. Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J Rheumatol 1993;20:259-62.
25. Masahiko M, Kotoh M, Oda Y et al. Anti-IL-6 receptor antibody suppresses the onset of collagen arthritis in monkeys. Arthritis Rheum 1997;36:S133.
26. Moreland LW, Baumgartner SW, Schiff MH et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-7.
27. Cutolo M, Kirkham B, Bologna C et al. Loading/ maintenance doses approach to neutralization of TNF by Lenercept (TNFR55-IgG1, Ro 45-2081) in patients with rheumatoid arthritis treated for 3 months: results of a double-blind placebo controlled phase II trial. Arthritis Rheum 1996;39(suppl.):S243.
28. Maini RN, Paulus H, Breedveld FC et al. rHUIL-10 in subjects with active rheumatoid arthritis (RA): A phase I and cytokine response study. Arthritis Rheum 1997;40(suppl.):S224.
29. Bresnihan B, on behalf of the collaborating investigators, Lookabaugh J, Witt K, Musikic P. Treatment with recombinant human interleukin-1 receptor antagonist (rhIL-1ra) in rheumatoid arthritis (RA): results of a randomized double-blind, placebo-controlled multicenter trial. Arthritis Rheum 1996;39(suppl.):S73.
30. Pitzalis C, Kingsley G, Panayi G. Adhesion molecules in rheumatoid arthritis: role in the pathogenesis and prospects for therapy. Ann Rheum Dis 1994;53:287-8.
31. Davis LS, Kavanaugh AF, Nichols LA, Lipsky PE. Alteration in circulating T cell subsets as a result of treatment of rheumatoid arthritis patients with a monoclonal antibody to intercellular adhesion molecule-1 (ICAM-1). Arthritis Rheum 1992;35:S43.
32. Kirkham BW, Pitzalis C, Kingsley GH et al. Monoclonal antibody treatment in rheumatoid arthritis: Clinical and immunological effects of a CD7 monoclonal antibody. Br J Rheumatol 1991;30:459-63.
33. Kirkham BW, Thien F, Pelton BK et al. Chimeric CD7 monoclonal antibody therapy in rheumatoid arthritis. J Rheumatol 1992;19:1348-52.
34. Lazarovits AI, White MJ, Karsh J. CD7-T cells in rheumatoid arthritis. Arthritis Rheum 1992;35:615-24.
35. Strand V, Lipsky PE, Cannon GW et al. Effects of administration of an anti-CD5 plus immunoconjugate in rheumatoid arthritis. Results of two phase II studies. The CD5 Plus Rheumatoid Arthritis Investigators Group. Arthritis Rheum 1993;36:620-30.
36. Olsen NJ, Brooks RH, Cush JJ et al. A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis. Arthritis Rheum 1996;39:1102-8.
37. Isaacs JD, Watts RA, Hazelman BL et al. Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet 1992;340:748-52.
38. Isaacs JD, Manna VK, Rapson N et al. Campath-1H in rheumatoid arthritis - an intravenous dose-ranging study. Br J Rheumatol 1996;35:231-40.
39. Ruderman EM, Weinblatt ME, Thurmond LM, Pinkus GS, Gravallese EM. Synovial tissue response to treatment with Campath-1H. Arthritis Rheum 1995;38:254-8.
40. Choy EHS, Chikanza IC, Kingsley GH, Corrigall V, Panayi GS. Treatment of rheumatoid arthritis with single dose or weekly pulses of chimaeric anti-CD4 monoclonal antibody. Scand J Immunol 1992;36:291-8.
41. Choy EH, Pitzalis C, Cauli A et al. Percentage of anti-CD4 monoclonal antibody-coated lymphocytes in the rheumatoid joint is associated with clinical improvement. Implications for the development of immunotherapeutic dosing regimens. Arthritis Rheum 1996;39:52-6.
42. Van den Broek MF, Van de Langerijt LG, Van Bruggen MC, Billingham ME, Van den Berg WB. Treatment of rats with monoclonal anti-CD4 induces long-term resistance to streptococcal cell wall-induced arthritis. Eur J Immunol 1992;22:57-61.
43. Panayi GS, Choy EHS, Connolly DJA et al. T cell hypothesis in rheumatoid arthritis (RA) tested by humanised non-depleting anti-CD4 monoclonal antibody (mAb) treatment I: suppression of disease activity and acute phase response. Arthritis Rheum 1996; 39(suppl.):S244.
44. Levy R, Weisman M, Wiesenhutter C et al. Results of a placebo-controlled, multicenter trial using a primatized, non-depleting, anti-CD4 monoclonal antibody in the treatment of rheumatoid arthritis. Arthritis Rheum 1996;39(suppl.):S122.
45. Lanes SF, Lanza LL, Radensky PW et al. Resource utilization and cost of care for rheumatoid arthritis and osteoarthritis in a managed care setting. Arthritis Rheum 1997;40:1475-81.
46. Comer M, Scott DL, Doyle DV, Huskisson EC, Hopkins A. Are slow-acting anti-rheumatic drugs monitored too often? An audit of current clinical practice. Br J Rheumatol 1995;34:966-70.
47. Matteson EL, Yocum DE, St Clair EW et al. Treatment of active refractory rheumatoid arthritis with humanized monoclonal antibody CAMPATH-1H administered by daily subcutaneous injection. Arthritis Rheum 1995; 38:1187-93.